Author: biocytogen

PEGS Boston Virtual Summit

August 20, 2020

Presentation Title: Accelerating Therapeutic Antibody Discovery with Three Distinct Humanized Mouse Models Time: 9:45 AM – 10:10 AM EDT on Monday, August 31 Programs: Antibody for Cancer Therapy  Speaker: Qingcong Lin, PhD, CEO, Biocytogen Boston Corp. With a robust immune response, RenMab™ Mouse produces fully-human antibodies with high specificity and diverse epitopes. To identify leads, […]

Read More

RenMab™ Mouse Platform Drives SARS CoV-2 Neutralizing Antibody Cocktail Therapy Towards Clinical Trials in Biocytogen and Eucure Biopharma Partnership

August 13, 2020

[MA, USA and Beijing, China – August]  The COVID-19 pandemic has been an inescapable, lethal, and overwhelming aspect of daily human life, threatening health and safety on a global scale. Biocytogen is excited to announce a breakthrough in scientific research and development (R&D) of therapeutic treatment strategy against the novel SARS CoV-2 viral spike protein […]

Read More

Webinar: Antibody Discovery Platforms and RenMab Mouse

June 29, 2020

This event has now passed. Now, you can view the Webinar on Youtube.  Biocytogen Chief Scientific Officer and Head of Drug Discovery, Benny Yang PhD. will speak on the current landscape of antibody discovery platforms, with special focus on fully human antibody mice. Dr. Yang will explain the advantages and data-backed validation that come with using the RenMabTM Mouse for antibody discovery such as expedited screening of antibody […]

Read More

Webinar: Humanized Animal Models for Immunotherapy

June 29, 2020

 This event has now passed. Now, you can view the Webinar on Youtube.   Topic: Improve Translation of Humanized Animal Models for Immunotherapy Date: Thursday, July 16 2020, 11am-12pm EST. Webinar Description: Despite significant advances have been made in developing novel therapeutics for cancer treatment, only about five percent of new cancer drugs are approved, […]

Read More

Syngeneic Mouse Models and Humanized Immune-Checkpoint Mice

June 17, 2020

Why do we need Syngeneic Mouse Models? To test potential immuno-oncology therapeutics in vivo, it is necessary to ensure that the disease model used has an intact immune system. Immunotherapeutics work with the body’s immune system to fight cancer cells. Often through inhibiting specific cell receptors called immune checkpoints, immunotherapeutics seek to bind to receptors […]

Read More

Online: Tumor Models Boston Summit 2020

June 17, 2020

In Vivo Efficacy & Toxicity Evaluation Using Various Humanized Mouse Models to Increase Clinical Translation Time: Saturday, July 15 2020. 9:30 AM EST. Speaker: Qingcong Lin, CEO of Biocytogen Boston Corp Discuss and evaluate IO target humanized mouse models, including hCD3e models for IO antibody efficacy evaluation How can Cytokine/Cytokine receptor humanized mouse models be used […]

Read More

AACR Virtual Annual Meeting II (Poster Session)

June 3, 2020

The AACR Foundation is the philanthropic arm of the American Association for Cancer Research (AACR). The Foundation supports the groundbreaking work of the AACR and its more than 47,000 members on the front lines of the global effort to eradicate cancer. The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer […]

Read More

Biocytogen is Featured in GEN’s Immunotherapy and Cancer Supplement Issue

April 10, 2020

Developing animal models for immunotherapy is often difficult due to the complexity of the immune system and tumor biology. Showcased in April’s GEN Magazine, Biocytogen presents a line of target-humanized mice models, covering a growing portfolio of immune checkpoints and cytokines alongside its flagship RenMab fully human antibody mouse. Biocytogen has also developed the immunodeficient […]

Read More

Biocytogen CEO’s Response During COVID-19 Pandemic

April 8, 2020

Dear Valued Customer, The COVID-19 global outbreak has undoubtedly brought upon difficult times for individuals, families, and businesses around the world. Many of us have never experienced an interruption of life at this scale. Amid this turmoil, I wanted to provide some status updates. Today, I am very glad to let you know that all […]

Read More

Back to top